関連ニュース

BioCryst Pharmaceuticals NASDAQ: BCRX is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Exec

BioCryst Pharmaceuticals, Inc.'s shares remain under pressure. At the same time, Orladeyo revenue increased 6.7% QoQ to $158.2 million in the second quarter. BioCryst's royalty financing obligations d

BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals. As large drugmakers prioritize multibillion dollar assets, small and midsize b